Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 3Prostatic Neoplasms 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Kidney Neoplasms 2Hodgkin Disease 2Carcinoma, Renal Cell 2Breast Neoplasms 2von Hippel-Lindau Disease 1Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocythemia, Essential 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Polycythemia Vera 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1

Interventions

tanespimycin 1pemigatinib 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Malignancies × tanespimycin × Clear all
NCT00779428 2015-10-12

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

Bristol-Myers Squibb

Phase 2 Completed
6 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡